1,349 reports of this reaction
2.1% of all IPILIMUMAB reports
#10 most reported adverse reaction
INTENTIONAL PRODUCT USE ISSUE is the #10 most commonly reported adverse reaction for IPILIMUMAB, manufactured by E.R. Squibb & Sons, L.L.C.. There are 1,349 FDA adverse event reports linking IPILIMUMAB to INTENTIONAL PRODUCT USE ISSUE. This represents approximately 2.1% of all 65,125 adverse event reports for this drug.
Patients taking IPILIMUMAB who experience intentional product use issue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INTENTIONAL PRODUCT USE ISSUE is a less commonly reported adverse event for IPILIMUMAB, but still significant enough to appear in the safety profile.
In addition to intentional product use issue, the following adverse reactions have been reported for IPILIMUMAB:
The following drugs have also been linked to intentional product use issue in FDA adverse event reports:
INTENTIONAL PRODUCT USE ISSUE has been reported as an adverse event in 1,349 FDA reports for IPILIMUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
INTENTIONAL PRODUCT USE ISSUE accounts for approximately 2.1% of all adverse event reports for IPILIMUMAB, making it a notable side effect.
If you experience intentional product use issue while taking IPILIMUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.